白藜芦醇载双棕榈酰磷脂酰胆碱脂质体大孔微粒吸入治疗鲍曼不动杆菌引起的细菌性肺炎。

IF 2 4区 医学 Q3 RESPIRATORY SYSTEM
Zicheng Yu, Tingting Wu, Xiaoyan Liu, Hongjun Chen, Chunxia Ren, Lifei Zhu
{"title":"白藜芦醇载双棕榈酰磷脂酰胆碱脂质体大孔微粒吸入治疗鲍曼不动杆菌引起的细菌性肺炎。","authors":"Zicheng Yu,&nbsp;Tingting Wu,&nbsp;Xiaoyan Liu,&nbsp;Hongjun Chen,&nbsp;Chunxia Ren,&nbsp;Lifei Zhu","doi":"10.1089/jamp.2021.0049","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> <i>Acinetobacter baumannii</i>-mediated bacterial pneumonia is a common disease that is harmful to human health. Dipalmitoylphosphatidylcholine (DPPC) is the major lipid component of the pulmonary surfactant (PS) found in the alveolar space; the PS helps to keep surface tension low, which allows for improved oxygen delivery. Resveratrol (RE) is a phytoalexin found in plants that is released in response to injury or infection. The therapeutic effect of Re is limited due to its low solubility and bioavailability. In this study, we report pulmonary delivery of Re-loaded DPPC liposomal large porous microparticles (RDLPMs) for treatment of <i>A. baumannii</i>-induced pneumonia. <b><i>Methods:</i></b> Novel RDLPMs were prepared by rotary evaporation and a freeze-drying method in this study. RDLPMs were evaluated by the particle size, electric potential, <i>in vitro</i> release, and particle size distribution. A rat model of <i>A. baumannii</i>-mediated pneumonia was established and used for pharmacodynamic evaluations. <b><i>Results:</i></b> The Re-loaded DPPC liposomes (RDLs) consisted of Re/DPPC (1:3, mol/mol) and DPPC/cholesterol (3:1, w/w), with a hydration time of 15 minutes. The RDLs had a high encapsulation efficiency of 69.8% ± 1.6%, a mean size of 191.5 ± 4.5 nm, and a high zeta potential of 12.4 ± 1.5 mV. The RDLPMs were composed of mannitol/large porous microparticles/RDLs (1:4:2, w/w/w) and had a loading efficiency of 2.20% ± 0.24%. The RDLPMs had an aerodynamic diameter (2.73 ± 0.65 μm), a good fluidity (28.30° ± 6.13°), and demonstrated high lung deposition (fine particle fraction = 43.33%). Surprisingly, while penicillin showed better microbial inhibition than the RDLPMs and Re groups <i>in vitro</i>, the RDLPMs were more effective <i>in vivo</i>. <b><i>Conclusion:</i></b> The RDLPMs showed good powder properties for pulmonary delivery. The RDLPMs may inhibit the nuclear factor kappa-B pathway and downregulate the expression of cytokines downstream of tumor necrosis factor-α and interleukin-1β. As well as, RDLPMs demonstrated some antibacterial properties against <i>A. baumannii</i> bacteria. Re, when delivered in RDLPMs as a dry powder inhaler, is a promising substitute for antibiotics in the treatment of <i>A. baumannii</i> pneumonia.</p>","PeriodicalId":14940,"journal":{"name":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","volume":"36 1","pages":"2-11"},"PeriodicalIF":2.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resveratrol-Loaded Dipalmitoylphosphatidylcholine Liposomal Large Porous Microparticle Inhalations for the Treatment of Bacterial Pneumonia Caused by <i>Acinetobacter baumannii</i>.\",\"authors\":\"Zicheng Yu,&nbsp;Tingting Wu,&nbsp;Xiaoyan Liu,&nbsp;Hongjun Chen,&nbsp;Chunxia Ren,&nbsp;Lifei Zhu\",\"doi\":\"10.1089/jamp.2021.0049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> <i>Acinetobacter baumannii</i>-mediated bacterial pneumonia is a common disease that is harmful to human health. Dipalmitoylphosphatidylcholine (DPPC) is the major lipid component of the pulmonary surfactant (PS) found in the alveolar space; the PS helps to keep surface tension low, which allows for improved oxygen delivery. Resveratrol (RE) is a phytoalexin found in plants that is released in response to injury or infection. The therapeutic effect of Re is limited due to its low solubility and bioavailability. In this study, we report pulmonary delivery of Re-loaded DPPC liposomal large porous microparticles (RDLPMs) for treatment of <i>A. baumannii</i>-induced pneumonia. <b><i>Methods:</i></b> Novel RDLPMs were prepared by rotary evaporation and a freeze-drying method in this study. RDLPMs were evaluated by the particle size, electric potential, <i>in vitro</i> release, and particle size distribution. A rat model of <i>A. baumannii</i>-mediated pneumonia was established and used for pharmacodynamic evaluations. <b><i>Results:</i></b> The Re-loaded DPPC liposomes (RDLs) consisted of Re/DPPC (1:3, mol/mol) and DPPC/cholesterol (3:1, w/w), with a hydration time of 15 minutes. The RDLs had a high encapsulation efficiency of 69.8% ± 1.6%, a mean size of 191.5 ± 4.5 nm, and a high zeta potential of 12.4 ± 1.5 mV. The RDLPMs were composed of mannitol/large porous microparticles/RDLs (1:4:2, w/w/w) and had a loading efficiency of 2.20% ± 0.24%. The RDLPMs had an aerodynamic diameter (2.73 ± 0.65 μm), a good fluidity (28.30° ± 6.13°), and demonstrated high lung deposition (fine particle fraction = 43.33%). Surprisingly, while penicillin showed better microbial inhibition than the RDLPMs and Re groups <i>in vitro</i>, the RDLPMs were more effective <i>in vivo</i>. <b><i>Conclusion:</i></b> The RDLPMs showed good powder properties for pulmonary delivery. The RDLPMs may inhibit the nuclear factor kappa-B pathway and downregulate the expression of cytokines downstream of tumor necrosis factor-α and interleukin-1β. As well as, RDLPMs demonstrated some antibacterial properties against <i>A. baumannii</i> bacteria. Re, when delivered in RDLPMs as a dry powder inhaler, is a promising substitute for antibiotics in the treatment of <i>A. baumannii</i> pneumonia.</p>\",\"PeriodicalId\":14940,\"journal\":{\"name\":\"Journal of Aerosol Medicine and Pulmonary Drug Delivery\",\"volume\":\"36 1\",\"pages\":\"2-11\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Aerosol Medicine and Pulmonary Drug Delivery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/jamp.2021.0049\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jamp.2021.0049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:鲍曼不动杆菌介导的细菌性肺炎是一种危害人类健康的常见病。双棕榈酰磷脂酰胆碱(DPPC)是肺泡间隙中肺表面活性物质(PS)的主要脂质成分;PS有助于保持较低的表面张力,从而改善氧气输送。白藜芦醇(Resveratrol, RE)是一种植物抗菌素,在植物受到伤害或感染时释放。由于其低溶解度和生物利用度,稀土的治疗效果受到限制。在这项研究中,我们报道了肺部递送重新装载的DPPC脂质体大孔微颗粒(rdlpm)用于治疗鲍曼杆菌引起的肺炎。方法:采用旋转蒸发法和冷冻干燥法制备新型rdlpm。采用粒径、电势、体外释放度、粒径分布等指标评价rdlpm。建立鲍曼不动杆菌介导的肺炎大鼠模型并进行药效学评价。结果:DPPC脂质体(RDLs)由Re/DPPC (1:3, mol/mol)和DPPC/胆固醇(3:1,w/w)组成,水化时间为15 min。rdl包封效率为69.8%±1.6%,平均尺寸为191.5±4.5 nm, zeta电位为12.4±1.5 mV。负载率为2.20%±0.24%,由甘露醇/大孔微粒/ rdlpm (1:4:2, w/w/w)组成。rdlpm的气动直径为2.73±0.65 μm,流动性良好(28.30°±6.13°),肺沉积量高(细颗粒分数为43.33%)。令人惊讶的是,青霉素在体外比rdlpm和Re组表现出更好的微生物抑制作用,而rdlpm在体内更有效。结论:rdlpm具有良好的肺给药粉末状特性。rdlpm可能抑制核因子κ b通路,下调肿瘤坏死因子-α和白细胞介素-1β下游细胞因子的表达。此外,rdlpm对鲍曼不动杆菌也有一定的抗菌作用。Re作为干粉吸入剂在rdlpm中给药时,是治疗鲍曼不动杆菌肺炎的有希望的抗生素替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Resveratrol-Loaded Dipalmitoylphosphatidylcholine Liposomal Large Porous Microparticle Inhalations for the Treatment of Bacterial Pneumonia Caused by Acinetobacter baumannii.

Background: Acinetobacter baumannii-mediated bacterial pneumonia is a common disease that is harmful to human health. Dipalmitoylphosphatidylcholine (DPPC) is the major lipid component of the pulmonary surfactant (PS) found in the alveolar space; the PS helps to keep surface tension low, which allows for improved oxygen delivery. Resveratrol (RE) is a phytoalexin found in plants that is released in response to injury or infection. The therapeutic effect of Re is limited due to its low solubility and bioavailability. In this study, we report pulmonary delivery of Re-loaded DPPC liposomal large porous microparticles (RDLPMs) for treatment of A. baumannii-induced pneumonia. Methods: Novel RDLPMs were prepared by rotary evaporation and a freeze-drying method in this study. RDLPMs were evaluated by the particle size, electric potential, in vitro release, and particle size distribution. A rat model of A. baumannii-mediated pneumonia was established and used for pharmacodynamic evaluations. Results: The Re-loaded DPPC liposomes (RDLs) consisted of Re/DPPC (1:3, mol/mol) and DPPC/cholesterol (3:1, w/w), with a hydration time of 15 minutes. The RDLs had a high encapsulation efficiency of 69.8% ± 1.6%, a mean size of 191.5 ± 4.5 nm, and a high zeta potential of 12.4 ± 1.5 mV. The RDLPMs were composed of mannitol/large porous microparticles/RDLs (1:4:2, w/w/w) and had a loading efficiency of 2.20% ± 0.24%. The RDLPMs had an aerodynamic diameter (2.73 ± 0.65 μm), a good fluidity (28.30° ± 6.13°), and demonstrated high lung deposition (fine particle fraction = 43.33%). Surprisingly, while penicillin showed better microbial inhibition than the RDLPMs and Re groups in vitro, the RDLPMs were more effective in vivo. Conclusion: The RDLPMs showed good powder properties for pulmonary delivery. The RDLPMs may inhibit the nuclear factor kappa-B pathway and downregulate the expression of cytokines downstream of tumor necrosis factor-α and interleukin-1β. As well as, RDLPMs demonstrated some antibacterial properties against A. baumannii bacteria. Re, when delivered in RDLPMs as a dry powder inhaler, is a promising substitute for antibiotics in the treatment of A. baumannii pneumonia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.70
自引率
2.90%
发文量
34
审稿时长
>12 weeks
期刊介绍: Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient. Journal of Aerosol Medicine and Pulmonary Drug Delivery coverage includes: Pulmonary drug delivery Airway reactivity and asthma treatment Inhalation of particles and gases in the respiratory tract Toxic effects of inhaled agents Aerosols as tools for studying basic physiologic phenomena.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信